Miami, USA-based Ridgeback Biotherapeutics has won US regulatory approval for a new Ebola virus treatment, Ebanga (ansuvimab-zykl).
The monoclonal antibody works by blocking binding of the Zaire ebolavirus to the cell receptor, preventing its entry into the cell.
Zaire ebolavirus is one of six variants of the rare but severe, often fatal illness, which has flared up multiple times in African countries since it was discovered in 1976.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze